Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Operating activities:
Net loss	$ (17,243)	$ (99,835)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	10,667	28,530
Depreciation and amortization	1,911	2,184
Amortization of debt discount	504	21
Amortization of debt issuance costs	157	155
Accretion of discount on short-term investments	(1,754)	(1,173)
Impairment of property and equipment	4,269	463
Loss on disposal of property and equipment		23
Change in operating assets and liabilities:
Accounts receivable	(6,902)	(11,746)
Inventory	(3,840)	12,566
Prepaid expenses and other assets	(3,769)	10,541
Accounts payable	6,948	(1,365)
Accrued clinical and manufacturing liabilities	208	272
Accrued payroll and employee liabilities	(693)	(3,040)
Other accrued and other non-current liabilities	(1,212)	1,160
Net cash used in operating activities	(10,749)	(61,244)
Investing activities:
Purchases of short-term investments	(90,745)	(64,309)
Maturities and sales of short-term investments	99,109	92,435
Purchases of property and equipment	(1,068)	(1,295)
Net cash provided by investing activities	7,296	26,831
Financing activities:
Net proceeds from private placement		29,755
Net proceeds from note financing		24,350
Receipts (payments) for stock issued under the equity incentive plan	342	(901)
Proceeds from purchases under the employee stock purchase plan	175	704
Net cash provided by financing activities	517	53,908
Net (decrease) increase in cash and cash equivalents	(2,936)	19,495
Cash and cash equivalents at beginning of year	28,677	15,364
Cash and cash equivalents at end of period	25,741	34,859
Supplemental disclosure of cash flow information:
Interest paid	$ 3,088	$ 1,288